Mike McGlone, Senior Commodity Strategist at Bloomberg Intelligence, explains why gold has reemerged as a superior hedge compared to Bitcoin, especially amid recent market turbulence. Sam Fazeli, Senior Pharmaceuticals Analyst, shares insights on the failed clinical trials of a pill version of Ozempic for Alzheimer's, highlighting the complexities of developing effective treatments. Media analyst Matthew Shettenhelm discusses the implications of easing broadcasting regulations, driven by President Trump's unpredictable tweets, and its impact on industry consolidation.
